Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy
PLEASANTON, Calif., July 28, 2026 /PRNewswire/ — Aqua Medical, Inc., a clinical-stage medical technology company pioneering Endoscopic Metabolic Restoration, today announced the successful treatment of the first U.S. patient in its U.S. Food and Drug Administration (FDA)-authorized Investigational Device Exemption (IDE) clinical trial evaluating the company’s proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes.
The landmark procedure was performed at UNC Health in Chapel Hill, North Carolina, one of only four leading U.S. academic medical centers selected to participate in the multicenter IDE clinical study. The procedure was led by Nicholas Shaheen, M.D., MPH, internationally recognized gastroenterologist, endoscopist, and National Principal Investigator of the study. The trial is being conducted in close collaboration with John B. Buse, M.D., Ph.D., one of the world’s leading endocrinologists and Co-Principal Investigator, whose pioneering work has helped shape modern diabetes care.
